Welcome!

News Feed Item

Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

The study, titled, A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer, evaluated the association of ChemoFx® results with disease progression for 276 FIGO stage III-IV ovarian, fallopian and peritoneal cancer patients treated with the standard of care first-line therapy carboplatin/paclitaxel. Patients whose tumors were scored as resistant by the ChemoFx test to carboplatin, were at significantly increased risk of disease progression compared to those with non-resistant tumors (median PFS: 11.8 vs. 16.6 months, respectively, p<0.001). The association was confirmed after adjusting for other clinical factors (HR=1.71, 95% CI=1.12-2.62, p=0.013). In addition to identifying platinum-resistant patients, the study also demonstrated the ability of ChemoFx to identify agents to which a patient’s tumor is sensitive. For 59% of those patients whose tumors proved resistant to carboplatin, at least one other commonly utilized agent was determined by ChemoFx to be sensitive or intermediately sensitive, indicating that these patients may benefit from alternative clinically validated treatments. These results further demonstrate the capability of the ChemoFx test to inform treatment decisions beyond the carboplatin/paclitaxel standard of care, particularly in cases where patients are unlikely to respond to the routine treatment.

Dr. Thomas C. Krivak, M.D., assistant director of gynecologic oncology and director of clinical research in gynecologic oncology at Allegheny Health Network, Department of Obstetrics and Gynecology, in Pittsburgh PA, is the primary author of the study.

“What the findings of this study essentially mean for ovarian cancer patients is that resistance to standard platinum chemotherapy treatment can now be determined much earlier in the treatment pathway with the use of ChemoFx results,” said Dr. Krivak. “Earlier determination of platinum resistance may help physicians choose the more effective treatments upfront, minimizing exposure to ineffective and often expensive therapy. Additionally, having further information about the tumor and chemotherapy resistance could substantiate augmenting standard of care with a third chemotherapy or with targeted agents.”

In addition to these findings, a recent, prospective study on recurrent ovarian cancer patients showed a 14 month improvement in median overall survival when patients were administered treatments identified as sensitive by ChemoFx vs. the non-sensitive treatments. “The combination of information this test provides is invaluable to physicians who are compelled to choose from a range of equivalent treatment recommendations without prior knowledge of how an individual patient may respond to any given treatment,” said Sean McDonald, CEO of Precision. “The ability of this test to determine platinum resistance in primary ovarian cancer patients and to demonstrate longer overall survival by 14 months in recurrent ovarian cancer, makes it an instrumental tool in helping to improve outcomes in ovarian cancer patients.”

About ChemoFx®

ChemoFx® is a proprietary drug response marker, which categorizes an individual patient’s tumor response to a range of standard chemotherapeutic options. Recently published prospective data demonstrates a 14-month improvement in overall survival (OS) when recurrent ovarian cancer patients are treated with therapy indicated as ‘responsive’ by the assay. ChemoFx may also help identify platinum-resistant/refractory primary ovarian patients earlier in their treatment pathway, aiding physicians with the selection of effective treatment upfront for patients newly diagnosed. Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalizing cancer care and improving patient outcomes. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s other leading products for personalized cancer care include:

  • BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
  • GeneFx® Colon, an expression–based gene signature developed for FFPE tissue from stage II colon cancer patients. Following surgery, GeneFx Colon assesses a patient’s risk of recurrence within 5 years.

For more information, visit www.precisiontherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While many government agencies have embraced the idea of employing cloud computing as a tool for increasing the efficiency and flexibility of IT, many still struggle with large scale adoption. The challenge is mainly attributed to the federated structure of these agencies as well as the immaturity of brokerage and governance tools and models. Initiatives like FedRAMP are a great first step toward solving many of these challenges but there are a lot of unknowns that are yet to be tackled. In hi...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
The proper isolation of resources is essential for multi-tenant environments. The traditional approach to isolate resources is, however, rather heavyweight. In his session at 18th Cloud Expo, Igor Drobiazko, co-founder of elastic.io, drew upon his own experience with operating a Docker container-based infrastructure on a large scale and present a lightweight solution for resource isolation using microservices. He also discussed the implementation of microservices in data and application integrat...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of Dev...
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
"LinearHub provides smart video conferencing, which is the Roundee service, and we archive all the video conferences and we also provide the transcript," stated Sunghyuk Kim, CEO of LinearHub, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.